14548-51-7

Basic information

• Product Name: 7-Bromo-3,4-dihydro-1H-quinolin-2-one
• Synonyms: 7-Bromo-3,4-dihydro-1H-quinolin-2-one;7-broMo-3,4-dihydroquinolin-2(1H)-one;7-BROMO-1,2,3,4-TETRAHYDRO-2-QUINOLINONE
• CAS NO: 14548-51-7
• Molecular Formula: C9H8BrNO
• Molecular Weight: 226.06992
• Mol File: 14548-51-7.mol

Chemical Properties

• Boiling Point: 359.1 °C at 760 mmHg
• Flash Point: 171 °C
• Appearance: /
• Density: 1.559 g/cm³
• Vapor Pressure: 2.43E-05mmHg at 25°C
• Refractive Index: 1.599
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 14.08±0.20(Predicted)
• CAS DataBase Reference: 7-Bromo-3,4-dihydro-1H-quinolin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Bromo-3,4-dihydro-1H-quinolin-2-one(14548-51-7)
• EPA Substance Registry System: 7-Bromo-3,4-dihydro-1H-quinolin-2-one(14548-51-7)

Safety Data

• Hazardous Substances Data: 14548-51-7(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
7-Bromo-3,4-dihydro-1H-quinolin-2-one is utilized as a key intermediate in the synthesis of various pharmaceuticals due to its unique structural features. Its presence in drug molecules can modulate their pharmacological properties, enhancing their efficacy and selectivity in treating specific medical conditions.
Used in Agrochemical Development:
In the agrochemical industry, 7-Bromo-3,4-dihydro-1H-quinolin-2-one is employed as a precursor in the creation of novel compounds with pesticidal or herbicidal properties. Its incorporation can lead to the development of more effective and environmentally friendly agrochemicals.
Used in Organic Synthesis:
As a building block in organic synthesis, 7-Bromo-3,4-dihydro-1H-quinolin-2-one is used to construct more complex organic molecules with diverse applications. Its versatility allows chemists to explore new pathways in molecular design, potentially leading to innovative materials and compounds.
Used in Biological Research:
7-Bromo-3,4-dihydro-1H-quinolin-2-one is studied for its potential biological activities, which may include roles in the treatment of various diseases. Its unique structure could offer new avenues for therapeutic intervention, making it a valuable compound in the ongoing quest for novel medical treatments.

InChI:InChI=1/C9H8BrNO/c10-7-3-1-6-2-4-9(12)11-8(6)5-7/h1,3,5H,2,4H2,(H,11,12)

Upstream product

• 1643-30-7 3-(4-bromophenyl)propionic acid 
• 501-52-0 3-Phenylpropionic acid 
• 14548-39-1 6-bromoindan-1-one 

Downstream Products

• 903557-01-7 2-oxo-1,2,3,4-tetrahydroquinoline-7-carbonitrile 
• 114744-51-3 7-bromo-1,2,3,4-tetrahydroquinoline 
• 1187932-64-4 tert-butyl 7-bromo-3,4-dihydroquinoline-1(2H)-carboxylate 
• 99465-10-8 7-bromo-1,2-dihydroquinolin-2-one 
• 1579950-30-3 7-{[3-(trifluoromethyl)phenyl]amino}-3,4-dihydroquinoline-2(1H)-one 

Relevant articles and documents

Visible-Light Induced C(sp2)?H Amidation with an Aryl–Alkyl σ-Bond Relocation via Redox-Neutral Radical–Polar Crossover

We report an approach for the intramolecular C(sp2)?H amidation of N-acyloxyamides under photoredox conditions to produce δ-benzolactams with an aryl-alkyl σ-bond relocation. Computational studies on the designed reductive single electron transfer strategy led us to identify N-[3,5-bis(trifluoromethyl)benzoyl] group as the most effective amidyl radical precursor. Upon the formation of an azaspirocyclic radical intermediate by the selective ipso-addition with outcompeting an ortho-attack, radical–polar crossover was then rationalized to lead to the rearomative ring-expansion with preferential C?C bond migration.

Triazole derivative having HSP90 (Heat Shock Protein) inhibiting activity, as well as preparation method and application of triazole derivative

The invention discloses a triazole derivative having an HSP90 (Heat Shock Protein) inhibiting activity, as well as a preparation method and an application of the triazole derivative. Specifically, the invention relates to the triazole derivative having a structure as shown in a formula (I), a stereisomer of the triazole derivative and a pharmaceutically acceptable salt, wherein the definition of each substituent group in the formula (I) and the definition in a description are the same. The compound with a novel structure has the HSP90 inhibiting activity, can be used to cure cancers, neurodegenerative disorders, inflammation diseases, autoimmune diseases, ischemic brain injuries and the like, and has a broad application prospect.

Structure-guided rescaffolding of selective antagonists of BCL-X L

Because of the promise of BCL-2 antagonists in combating chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL), interest in additional selective antagonists of antiapoptotic proteins has grown. Beginning with a series of selective, potent BC

7-PIPERIDINOALKYL-3,4-DIHYDROQUINOLONE DERIVATIVE

To provide a novel compound, a pharmaceutically acceptable salt or a hydrate thereof useful for preventing or treating for depression, anxiety disorders (such as generalized anxiety disorder, posttraumatic stress disorder, panic disorder, obsessive-compulsive disorder or social anxiety disorder), attention deficit disorder, mania, manic-depressive illness, schizophrenia, mood disorders, stress, sleep disorders, attacks, memory impairment, cognitive impairment, dementia, amnesia, delirium, obesity, eating disorder, appetite disorder, hyperphagia, bulimia, cibophobia, diabetes, cardiovascular diseases, hypertension, dyslipidemia, myocardial infarction, movement disorder (such as Parkinson's disease, epilepsy, convulsion or tremor), drug abuse, drug addiction or sexual dysfunction, based on a melanin-concentrating hormone receptor (MCH receptor) antagonistic action. SOLUTION A compound, a pharmaceutically acceptable salt or a hydrate thereof represented by the formula (I).